No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group (Q114069484)
Jump to navigation
Jump to search
scientific article published in 2022
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group |
scientific article published in 2022 |
Statements
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group (English)
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Tamara Castaño-Bonilla
1 reference
Eva Barragán
1 reference
Claudia Sargas
1 reference
Alejandro Sanz
1 reference
Lorenzo Algarra
1 reference
Pilar Herrera-Puente
1 reference
Raimundo García-Boyero
1 reference
Manuel Barrios
1 reference
Cristina Gil
1 reference
Josefina Serrano-López
1 reference
María José Sayas-Lloris
1 reference
María Teresa Olave
1 reference
Rosalía Riaza-Grau
1 reference
Teresa Bernal-Del Castillo
1 reference
María José Larrayoz
1 reference
Raquel Amigo
1 reference
Joaquín Sánchez
1 reference
Carlos Blas
1 reference
23 August 2022
1 reference
1 reference
2022
1 reference
1-9
1 reference
23 August 2022
1 reference